TCS recognized as a Leader and Star Performer in Life Sciences Clinical and R&D IT Services by Everest Group
Report Cites TCS' Platform Driven Approach, Strong Growth, Investments and Execution Experience as Key Attributes
NEW YORK | MUMBAI, August 18, 2017: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organization, has been recognized as a Leader and Star Performer for Life Sciences Clinical and R&D IT Services by leading advisory and research firm, Everest Group, in its report, “Life Sciences Clinical and R&D IT Services – Service Provider Landscape with PEAK Matrix™ Assessment 2017.”
Everest Group acknowledged TCS’ strong foothold in the pharmaceutical and medical devices sector and a growing business presence with biotechnology firms. The report highlights TCS’ strong growth in strategic clinical and R&D space with solutions such as Advanced Drug Development Platform and Connected Clinical Trials and consistent execution excellence. In addition, TCS is recognized for its significant investments in gene-based therapeutics and connected healthcare and an emerging platform play in clinical and R&D areas.
Everest Group analyzed 18 leading service providers on the Everest Group PEAK Matrix specific to Life Sciences Clinical and R&D IT services, categorizing them into Leaders, Major Contenders, and Aspirants. The PEAK Matrix is a composite framework that provides an objective, data-driven and comparative assessment of Life Sciences Clinical and R&D IT service providers based on their absolute market success and delivery capability.
“Life Sciences companies need to reinvent Clinical and R&D processes given disruptive market dynamics and they are using technology and analytics as key levers to manage this change. There is a need to compress cycle times, improve cost efficiency and drive precision medicine efforts,” said Jimit Arora, Partner, Everest Group. “TCS, with its investments in gene-based therapeutics and connected healthcare, combined with an emerging platform play is establishing itself as a partner of choice for Life Sciences firms.”
“Digital disruption is creating opportunities for the Life Sciences industry to accelerate the drug development process while emphasizing patient engagement, personalized medicine and connected health,” said Debashis Ghosh, President - Life Sciences, Healthcare, Government and Energy Business Group, TCS. “TCS has developed innovative solutions and platforms using cognitive technology, advanced analytics and rich domain expertise to fully digitize drug development process, reduce cycle time, and enhance R&D productivity while ensuring compliance.”
About TCS Life Sciences
TCS Life Sciences provides top global Life Sciences organizations full service offerings in IT, Consulting, KPO, Infrastructure and Engineering Services, as well as Digital Solutions using Mobility, Big Data, Analytics, and Cloud. TCS’ rich industry experience, domain expertise and global footprint allows for a seamless partnership with its Life Sciences customers to help them advance clinical trial efficiencies, accelerate drug discovery, accentuate manufacturing productivity, and amplify sales and marketing effectiveness. In addition, TCS has a dedicated Life Sciences Innovation Lab which ensures that its customers have the tools and innovative solutions they need to solve complex business challenges.
About Tata Consultancy Services Ltd. (TCS)
Tata Consultancy Services is an IT services,consulting and business solutions organization that delivers real results to global business, ensuring a level of certainty no other firm can match. TCS offers a consulting-led, integrated portfolio of IT, BPS, infrastructure, engineering and assurance services. This is delivered through its unique Global Network Delivery Model™, recognized as the benchmark of excellence in software development. A part of the Tata group, India’s largest industrial conglomerate, TCS has over 385,000 of the world’s best-trained consultants in 46 countries. The company generated consolidated revenues of US $17.58 billion for year ended March 31, 2017 and is listed on the BSE Limited and National Stock Exchange of India Limited. For more information, visit us at www.tcs.com.
TCS Media Contacts
Phone: +91 22 6778 9999
Phone: +44 20 3155 2421
Phone: +91 22 6778 9078 | +91 22 6778 9081
Phone: +1 646 313 4594
Australia and New Zealand
Phone: +61 488 403 013
Phone: +569 6170 9013
Phone: +81 80-2115-0989